Aveanna Healthcare Holdings (NASDAQ: AVAH) to acquire Trivest-backed Family First Homecare, expanding pediatric home care footprint and leveraging cash and credit facilities for accretive growth via its financial sponsors Bain Capital and J.H. Whitney Capital Partners Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) agreed to acquire Family First Holding, LLC, a multi-state pediatric home care provider backed by growth investor Trivest Partners since 2021, in a strategic platform expansion deal. The transaction, funded through cash on hand and Aveanna’s existing short-term credit facility, is expected to close in Q2 2026 subject to customary conditions, underscoring lender confidence in the issuer’s credit profile. For Trivest, the exit crystallizes value created since its minority investment, while Aveanna investors gain access to 27 locations across seven states and deeper exposure to high-acuity, home-based pediatric care. Management highlights the acquisition as aligned with Aveanna’s strategy to scale specialized care models and deliver enhanced value to payors and stakeholders. (Link)
Veeva Systems (NYSE: VEEV) pays $100 million for AI brand engagement platform Ostro, enhancing life sciences commercial cloud offering Veeva Systems Inc. (NYSE: VEEV) has acquired Ostro, an AI-powered brand engagement platform, for $100 million to strengthen its commercial suite for life sciences clients. The acquisition integrates AI-driven customer engagement and personalization into Veeva’s CRM and marketing stack. Shareholders gain incremental growth opportunities as pharma and biotech customers increase digital and AI spend. The all-cash deal aligns with Veeva’s strategy of adding focused applications that drive higher wallet share and stickiness across large enterprise accounts. (Link)
Medtronic (NYSE: MDT) to acquire neurovascular device company, Scientia Vascular, for $550 million, bolstering high-growth stroke and neuro interventions pipeline.Medtronic plc (NYSE: MDT) has agreed to acquire a neurovascular device company, Scientia Vascular, for approximately $550 million, targeting expansion in stroke and neuro-interventional therapies. The acquisition enhances Medtronic’s innovation pipeline and positions the company to compete more aggressively in high-growth, procedure-driven markets. Equity investors in Medtronic gain exposure to a differentiated product portfolio that can support long-term revenue growth and margin expansion. The transaction will likely be funded through Medtronic’s balance sheet and is consistent with its strategy of bolt-on acquisitions in key therapy areas. (Link)
RadNet (NASDAQ: RDNT) to acquire AI radiology company Gleamer, advancing imaging AI capabilities and strengthening diagnostic services moat. RadNet, Inc. (NASDAQ: RDNT) has agreed to acquire Gleamer, an AI radiology company, to integrate advanced AI tools into its large-scale imaging network. The acquisition is expected to enhance diagnostic accuracy, workflow efficiency, and throughput across RadNet’s centers. Equity investors view the move as strategic positioning in AI-enabled diagnostics, potentially improving margin structure and differentiation against competitors. The deal also gives Gleamer’s technology a scaled deployment channel, increasing data volume and algorithm performance over time. (Link)
MedImpact Holdings acquires MHW Benefit Partners and MSL Captive Solutions to build integrated risk and pharmacy benefits platform for self-funded employers. MedImpact Holdings, Inc., a leading independent health solutions and pharmacy benefit company, acquired MHW Benefit Partners and MSL Captive Solutions to expand its suite of alternative risk-financing offerings for employer clients. The deal broadens MedImpact’s capabilities into captives and stop-loss insurance, enabling small and mid-sized employers to access structures historically used by large self-insured groups. Investors in MedImpact gain exposure to higher-margin, capital-efficient risk-management services that complement the core PBM and clinical programs. The acquisitions are expected to drive cross-sell opportunities across TPAs, transparent networks, drug savings, and member care solutions, deepening client stickiness and recurring revenue. (Link)
Prospect Medical Holdings sells final Crozer hospital for $1 million, marking distressed exit from Pennsylvania market and transfer to local nonprofit sponsor. Prospect Medical Holdings has completed the divestiture of its final Crozer Health hospital for approximately $1 million, effectively exiting its troubled Pennsylvania hospital portfolio. The low valuation underscores ongoing financial distress and operational challenges in safety-net acute care assets, impacting prior private equity investors in the platform. The facility transitions to a local nonprofit sponsor, shifting governance away from financial sponsors toward mission-driven community operators. Lenders and bondholders will monitor post-transaction capital commitments and turnaround plans as the new owner seeks to stabilize operations and address deferred investment needs. (Link)
CSG.BIO partners with and Asian Egg Bank, adding specialized fertility assets backed by Corbel to its global reproductive health platform. CSG.BIO has entered a partnership with Hanabusa IVF and Asian Egg Bank, acquiring a specialized fertility clinic and donor egg bank focused on Asian patients to expand its reproductive health platform. The deal is supported by capital from Corbel, providing growth funding to scale the mini-IVF and donor egg offerings across new markets. Investors in CSG.BIO gain differentiated assets in a high-growth, cash-pay fertility segment with strong patient demand. The transaction reflects continued private equity and sponsor interest in fertility platforms with unique clinical models and demographic specialization. (Link)
BV Investment Partners takes stake in Moxe Health, backing healthcare data exchange platform in value-based care ecosystem. BV Investment Partners has made an investment in Moxe Health, a healthcare data exchange and interoperability platform focused on payor-provider connectivity. The capital infusion will support product development and commercial expansion as value-based care models require richer, real-time data flows. For BV’s limited partners, the deal offers exposure to a high-growth, recurring revenue SaaS model in healthcare IT infrastructure. Moxe plans to leverage the partnership to accelerate integrations with payors and providers, enhancing network effects and stickiness. (Link)
MedCare Express sold to physician group AMKY Health CT, LLC, transitioning a scaled urgent and primary care practice to new clinical owners. MedCare Express, an integrated urgent and primary care center serving over 30,000 active patients in the Greater Hartford area, has been sold to private physician practice group AMKY Health CT, LLC. Founded in 2007, MedCare Express has built a strong community footprint and recurring patient base, making it an attractive cash-flow asset for physician investors. The buyer plans to support growth while preserving quality standards, signaling a long-term, clinical-operator-led strategy rather than a near-term financial engineering approach. Existing stakeholders benefit from continuity of care and potential service expansion under new ownership. (Link)
Baptist Health to acquire South Arkansas Regional Hospital in El Dorado, extending nonprofit system’s regional footprint and strengthening community care. Baptist Health has signed an agreement to acquire South Arkansas Regional Hospital in El Dorado, Arkansas, adding a key community hospital to its regional nonprofit health system. The acquisition brings the hospital under a larger balance sheet, providing access to capital for facility upgrades and service expansion. For bondholders and donors supporting Baptist Health, the transaction represents a strategic bet on stabilizing rural and small-market acute care. Local stakeholders are expected to benefit from integration into Baptist’s broader clinical network and potential economies of scale in operations and procurement. (Link)
HouseWorks acquires A Caring Experience, scaling private-pay home care footprint and consolidating in the New England market via its financial sponsors InTandem Capital Partners and BPEA Private Equity HouseWorks, a home care provider backed by institutional investors, has acquired A Caring Experience to deepen its presence in the New England home care market. The deal adds local scale, enhances caregiver capacity, and broadens referral relationships in a competitive private-pay and Medicaid-waiver environment. Investors in HouseWorks are positioning for demographic tailwinds and further roll-up opportunities in non-medical home care. The combination is expected to generate operating synergies across scheduling, back-office functions, and recruitment, improving margin profile over time. (Link)
Dynamic Access acquires PICC STAT in Minnesota, expanding vascular access services footprint for clinical and financial sponsors via its financial sponsor RiverGlade Capital Dynamic Access has acquired PICC STAT, a Minnesota-based vascular access provider, in a tuck-in acquisition to grow its specialized PICC and vascular access services network. The deal strengthens Dynamic Access’s regional coverage, allowing payors and health systems to rely on a larger contracted network for on-demand vascular access. Financial sponsors backing outsourced clinical service platforms benefit from increased density, which supports higher route efficiency and utilization. The acquisition underscores ongoing consolidation in niche procedural services where scaled operators can secure better payer contracts and operating leverage. (Link)
Residential Home Health and Hospice acquires Covenant, building scale in home health and hospice across regional markets for sponsor-backed platform. Residential Home Health and Hospice has announced the acquisition of Covenant, adding a substantial home health and hospice footprint to its existing platform. The deal expands the provider’s presence across multiple states, increasing patient census and strengthening referral networks. Sponsor investors behind Residential are pursuing a scale and density strategy in post-acute care, where larger platforms can better manage labor, compliance, and payor relationships. The transaction positions the combined organization to capture more value in value-based and episodic payment arrangements. (Link)
Health Recovery Solutions acquires Rimidi, expanding remote care programs and chronic disease management capabilities for digital health investors. Health Recovery Solutions has acquired Rimidi to broaden its remote patient monitoring and chronic disease management solutions. The combined platform will offer providers and payors an integrated suite for virtual care, data analytics, and patient engagement. Investors see the transaction as consolidation in a crowded remote monitoring space, aiming to reach sustainable scale and differentiated outcomes data. The deal positions the company to participate more fully in value-based arrangements tied to chronic condition control. (Link)
Guideway Care acquires Waypoint Healthcare Solutions, expanding patient navigation and care coordination platform for payor and provider sponsors. Guideway Care has acquired Waypoint Healthcare Solutions to enhance its patient navigation and care coordination capabilities. The transaction deepens Guideway’s relationships with payors and providers seeking to reduce avoidable utilization and improve outcomes. Financial sponsors backing navigation and care-management platforms expect enhanced cross-sell and contract win rates from the expanded offering. The combined entity is positioned to integrate analytics, staffing, and workflow tools under a single, scalable model. (Link)
Centerpoint Health Winchester acquires local medical practice, expanding primary care capacity under community health center sponsorship. Centerpoint Health Winchester has announced the acquisition of a local medical practice, adding providers and patient volume to its community health operations. The deal supports Centerpoint’s mission-driven growth strategy, bringing more primary care access under a single organizational umbrella. For grantors and community-focused investors, the transaction aligns with population health and access objectives rather than pure financial returns. The additional capacity may improve economies of scale in administration and payer contracting for the center. (Link)
ECU Health agrees to sell home health and hospice unit to Liberty, pending state review, rebalancing portfolio toward core acute services ECU Health has agreed to sell its home health and hospice operations to Liberty, subject to state regulatory review. The divestiture allows ECU Health to refocus capital and management attention on its core acute care and hospital assets. Liberty, a home health and hospice operator, gains additional scale and access to new markets, enhancing network density for its investors and lenders. The transaction continues a broader trend of health systems exiting ancillary service lines to specialized operators. (Link)
Sonida Senior Living (NYS:SNDA) completes $1.8 billion strategic merger with CNL Healthcare Properties, deepening senior housing scale and institutional investor backing. Sonida Senior Living has closed a strategic merger with non-traded REIT CNL Healthcare Properties Inc., valuing the combined senior housing platform at approximately $1.8 billion and significantly increasing real estate scale for equity holders. The transaction gives Sonida access to a larger portfolio of senior living communities and a broader institutional capital base anchored by CNL’s healthcare-focused investors. The combined platform is positioned to pursue operational efficiencies, refinancings, and future portfolio optimization to enhance returns. Equity stakeholders in both entities gain from diversification across markets and care levels, while debt providers benefit from greater asset backing. (Link)
Biomemory acquires Catalog Technologies, preparing DNA data storage deployment in data centers in H2 2026 for deep-tech backers. DNA data storage startup Biomemory has acquired Catalog Technologies, consolidating IP and capabilities to commercialize DNA-based data storage solutions. The combined company plans data center deployments in the second half of 2026, targeting hyperscale and enterprise customers seeking ultra-dense, long-term storage. Deep-tech and climate-conscious investors see potential in DNA storage’s low energy footprint compared to traditional media. The acquisition accelerates time-to-market and strengthens Biomemory’s competitive position in a nascent but strategically important storage category. (Link)
Aditxt (NAS: ADTX) buys Ignite Proteomics for $36 million in preferred stock and secures $2.88 million note financing, strengthening precision medicine portfolio. Aditxt has acquired Ignite Proteomics in a stock-based transaction valued at $36 million in preferred equity, alongside securing $2.88 million in note financing. The deal brings proteomics capabilities into Aditxt’s precision medicine and immune monitoring portfolio, offering investors upside in biomarker-driven platforms. The structure, heavily equity-based with incremental debt, reflects a capital-efficient approach for a growth-stage company. Noteholders gain exposure to potential value inflection from integration and commercialization of Ignite’s technologies. (Link)
Venture Deals
Amigo AI Secures $11 Million Series A Led by Madrona to Scale Patient-Facing Clinical AI Agents with significant participation from Optum Ventures Amigo AI has successfully raised $11 million in a Series A funding round led by Madrona, with significant participation from Optum Ventures. This capital infusion brings the company’s total funding to $17 million, following a previous seed round supported by General Catalyst and GSV Ventures. The investment is earmarked for the expansion of Amigo’s “digital residency” platform, which trains AI agents in simulated clinical environments to ensure a 100% safety pass rate before patient interaction. For venture investors, Amigo represents a high-growth opportunity to address the global healthcare workforce shortage by automating complex clinical workflows like triage and care navigation across 100+ languages. (Link)
Arya Secures $21 Million Series A to Scale Relationship OS Platform for Modern Couples Arya has successfully raised $21 million in a Series A funding round led by Canvas Ventures, with participation from existing investors including General Catalyst and SV Angel. This capital injection is aimed at accelerating the development of its “Relationship OS,” a technology platform designed to help couples navigate emotional, financial, and logistical complexities through data-driven insights. For venture investors, the deal represents a strategic entry into the rapidly growing “Family Tech” and wellness space, leveraging AI to provide personalized coaching and conflict-resolution tools. The funding will support product engineering and the expansion of Arya’s user base as it seeks to define a new category of proactive mental health and relationship maintenance. (Link)
Carefam Raises $10.5 Million to Scale AI-Driven Healthcare Recruitment Platform led by Pitango Venture Capital Carefam has successfully raised $10.5 million in a new funding round, bringing its total capital raised to $14 million. The investment is aimed at expanding its specialized conversational AI platform, which automates the end-to-end hiring process for hospitals, long-term care facilities, and home care providers. For venture investors, Carefam addresses the critical global healthcare labor shortage by streamlining credential screening, interview scheduling, and onboarding through vertically integrated AI agents. The funding will allow the company to enhance its technology and scale its operations to help healthcare HR departments reduce administrative friction and accelerate the placement of essential clinical staff. (Link)
Qualified Health Eyes Series A Funding Following $30 Million Seed Round Led by SignalFire, Healthier Capital, and Town Hall Ventures Qualified Health, a pioneer in healthcare orchestration, is reportedly preparing for a Series A funding round to scale its AI-driven platform that streamlines clinical and administrative workflows. This follows a substantial $30 million seed investment led by SignalFire, Healthier Capital, and Town Hall Ventures, which allowed the company to deploy its “operating layer” across major systems like University of Texas and Jefferson Health. For venture investors, the startup represents a high-potential infrastructure play that integrates with EHRs to automate summarization and prior authorization. Potential new investors such as NEA and General Catalyst are being watched as the company targets a nine-figure valuation while navigating rigorous generative-AI safety and regulatory hurdles. (Link)
Translucent Secures $27 Million Series A Led by GV (Google Ventures) to Revolutionize Healthcare Financial Operations Translucent has closed a $27 million Series A funding round led by GV, with participation from existing investors including Benchmark and Unusual Ventures. This capital injection is dedicated to scaling the company’s AI-driven financial orchestration platform, which targets the “existential financial crisis” facing hospitals by automating complex revenue cycle and accounts payable workflows. For venture investors, Translucent represents a critical infrastructure play that addresses thin hospital margins through autonomous financial intelligence. The funding will be used to accelerate product development and expand the company’s footprint across health systems seeking to replace manual, error-prone administrative tasks with real-time, transparent financial data management. (Link)
Race to Contain Iran War Oil Shock as Crude Surges Past 100 Dollars, Markets Slide and Fears Grow Over Prolonged Energy Disruption and Global Inflation Spike G7 finance ministers are preparing an emergency meeting to discuss a possible coordinated release of strategic oil reserves after the Iran war pushed crude above 100 dollars a barrel for the first time since 2022, with Brent briefly nearing 120 dollars. The US‑Israel conflict with Iran has severely disrupted shipments through the Strait of Hormuz, a route that normally carries about a fifth of global oil, driving a sharp spike in crude and gas prices and triggering stock‑market falls. G7 officials fear prolonged fighting could keep energy flows constrained, entrench higher inflation and slow global growth. (Link)
Universal Health Services (NYSE: UHS) to Acquire Talkspace (NASD: TALK) for $5.25/Share in $835 Million All‑Cash Deal to Build National Virtual Behavioral Health Platform Universal Health Services (UHS) has signed a definitive agreement to acquire virtual behavioral health provider Talkspace for $5.25 per share, implying an enterprise value of about $835 million, funded via UHS’s existing revolving credit facility. Talkspace, which generated roughly $229 million in 2025 revenue and delivered more than 1.6 million therapy and psychiatry sessions, brings a network of about 6,000 licensed professionals across all U.S. states, D.C. and Puerto Rico. UHS expects the deal, unanimously approved by both boards and targeted to close in Q3 2026 pending shareholder and regulatory approvals, to be slightly accretive to adjusted EPS in the first year and to accelerate its outpatient and telehealth behavioral health strategy. (Link)
Agilent Technologies (NYSE: A) to Acquire Biocare Medical for $950 Million Cash, Expanding High-Growth Pathology Antibody Platform and Targeting EPS Accretion Within 12 Months Agilent Technologies (NYSE: A) has signed a definitive agreement to acquire Biocare Medical, a high-growth clinical pathology specialist, in an all-cash deal valued at $950 million. Biocare, a leader in IHC, ISH and FISH solutions with more than 300 antibodies and over $90 million of 2025 revenue, has delivered double-digit revenue and profit growth since 2021. The transaction will expand Agilent’s pathology portfolio, strengthen its U.S. footprint and accelerate antibody menu development. Management expects the deal to be accretive to growth, margins and non-instrument mix in year one and to EPS about 12 months post-close. (Link)
Saisystems Health and Serent Capital Partner to Scale AI-Enabled RCM and EHR Solutions Saisystems Health, a provider of technology-enabled revenue cycle management (RCM) and electronic health records (EHR) for post-acute care, has announced a strategic partnership with private equity firm Serent Capital. While the specific financial terms were not disclosed, the investment is aimed at accelerating Saisystems’ product innovation, specifically enhancing its AI capabilities to streamline clinical workflows and financial performance for skilled nursing facilities and physician groups. The partnership leverages Serent’s expertise in scaling healthcare technology companies to expand Saisystems’ market footprint. (Link)
Integration Health Expands Portfolio with Acquisition of Perfusion Life via its financial sponsor 1315 Capital Integration Health has successfully completed the acquisition of Perfusion Life, a leading provider of perfusion staffing and management services. This strategic move is designed to bolster Integration Health’s clinical service offerings across hospitals and surgical centers. By integrating Perfusion Life’s specialized expertise, Integration Health aims to optimize cardiovascular surgical support and staffing efficiency. The acquisition reflects a broader strategy of consolidating niche clinical services to provide a more comprehensive, integrated care delivery model for healthcare systems nationwide. (Link)
Surgery Partners Acquires Preferred Vascular Group to Expand Multispecialty Surgical Platform its financial sponsor Bain Capital Surgery Partners, Inc. has acquired Preferred Vascular Group (PVG), a provider of vascular care services. This acquisition integrates PVG’s high-quality vascular access centers into Surgery Partners’ extensive national network of ambulatory surgical centers. The deal is intended to enhance Surgery Partners’ specialty care capabilities, particularly in the outpatient vascular space, providing patients with more accessible and cost-effective treatment options. This move follows trends of shifting high-acuity procedures to lower cost, outpatient environments. (Link)
Gedeon Richter Expands Women’s Health Portfolio through Acquisition of Celmatix’s Drug Discovery Assets Global pharmaceutical company Gedeon Richter has acquired the women’s health drug discovery portfolio from Celmatix Inc. The deal includes several preclinical programs focused on first-in-class treatments for conditions such as PCOS and endometriosis. This acquisition strengthens Gedeon Richter’s position as a leader in women’s healthcare by integrating Celmatix’s AI-driven “Transcriptomic Cohort” data to identify novel therapeutic targets. The partnership emphasizes a shared commitment to addressing underserved medical needs in reproductive health through cutting-edge genomic research and clinical development. (Link)
Quantum Health Bolsters Virtual Care Strategy with Acquisition of CirrusMD via its financial sponsors Great Hill Partners and Warburg Pincus. Quantum Health, a leading consumer healthcare navigation company, has acquired CirrusMD, a provider of physician-led integrated virtual care. This acquisition enables Quantum Health to integrate CirrusMD’s “text-first” virtual care platform into its navigation services, offering members immediate access to physicians. The synergy aims to reduce healthcare costs and improve outcomes by closing gaps in care through early intervention. The deal reflects Quantum Health’s strategy to provide a seamless, end-to-end healthcare experience that combines human navigation with advanced digital health tools. (Link)
TPG Capital Partners with Findhelp to Enhance Social Care Access for Underserved Populations Global alternative asset firm TPG, through its Rise Fund, has partnered with Findhelp, the leading social care network in the United States. The investment is geared toward scaling Findhelp’s platform, which connects individuals in need with local social service organizations. TPG’s involvement will support Findhelp in expanding its reach among healthcare providers, insurers, and government agencies. By addressing social determinants of health (SDOH), the partnership aims to improve health outcomes and equity for millions of Americans by streamlining the referral process for food, housing, and financial assistance. (Link)
American Reproductive Centers Acquires Mississippi Fertility Institute for $4.25 Million Alabama-based American Reproductive Centers (ARC) has expanded its regional presence by acquiring the Mississippi Fertility Institute in a deal valued at $4.25 million. This acquisition is part of ARC’s strategic effort to increase access to advanced reproductive technologies and fertility treatments across the Southeast. By integrating the Jackson-based clinic into its network, ARC plans to upgrade facilities and introduce new clinical protocols to improve patient success rates. The deal underscores a growing trend of regional consolidation within the highly specialized fertility and IVF market. (Link)
DoseSpot and Arrive Health Merge to Improve Prescription Access and Price Transparency via its financial sponsors Bain Capital Tech Opportunities, PSG and UPMC Enterprises DoseSpot, a leading e-prescribing platform, and Arrive Health, a provider of real-time prescription benefit tools, have announced a merger. This combination aims to create a unified platform that integrates clinical workflows with financial transparency, allowing clinicians to see accurate drug pricing at the point of care. The merger is designed to improve medication adherence and reduce administrative burdens for providers. By joining forces, the entities seek to solve the critical challenge of drug affordability, ensuring patients can access the most cost-effective medications prescribed by their doctors. (Link)
Adobe Population Health Acquires Eventa LLC to Integrate Respiratory Care Solutions Adobe Population Health has expanded its clinical service suite through the acquisition of Eventa LLC, a specialist in respiratory care management. This acquisition allows Adobe to offer specialized services for patients with chronic respiratory conditions, such as COPD and asthma, within its population health management framework. By incorporating Eventa’s expertise, Adobe aims to reduce hospital readmissions and improve the quality of life for high-risk patient populations. The move highlights Adobe’s commitment to building a comprehensive, multi-disciplinary approach to managing complex chronic diseases. (Link)
Freeman Health System to Acquire Four Arkansas Hospitals from Community Health Systems (CHS) Community Health Systems (CHS) has signed a definitive agreement to sell four of its Arkansas-based hospitals to Freeman Health System. The transaction includes facilities in El Dorado, Springdale, and Bentonville. This divestiture is part of CHS’s ongoing portfolio optimization strategy to focus on core markets. For Freeman Health System, the acquisition represents a significant geographic expansion, allowing the non-profit system to provide a broader continuum of care to residents in the Arkansas region while investing in facility upgrades and clinical services. (Link)
MUSC Health Expands Statewide with $111 Million Acquisition of Palmetto Primary Care MUSC Health has announced a $111 million deal to acquire Palmetto Primary Care Physicians, one of the largest independent multi-specialty groups in South Carolina. This strategic acquisition significantly broadens MUSC’s primary care footprint, adding over 100 providers across 30 locations. The investment is focused on creating a more seamless “hub-and-spoke” model of care, ensuring patients have easier access to MUSC’s specialized academic medical services through their local primary care offices. The deal reflects MUSC’s mission to provide comprehensive, integrated healthcare coverage throughout the state. (Link)
Seal Shield Acquires Vioguard to Expand UV-C Sanitization Solutions in Healthcare Seal Shield, a leader in medical-grade infection control hardware, has acquired Vioguard, a pioneer in UV-C LED disinfection technology. This acquisition enhances Seal Shield’s portfolio of sanitization solutions designed to eliminate pathogens on high-touch surfaces in clinical environments. By integrating Vioguard’s patented UV-C technology, Seal Shield aims to offer more robust, automated disinfection tools to hospitals and clinics, helping to reduce healthcare-associated infections (HAIs). The deal positions Seal Shield as a comprehensive provider of both antimicrobial hardware and advanced disinfection systems. (Link)
National Healthcare Properties and Discovery Senior Living Complete $64 Million Acquisition National Healthcare Properties, in partnership with Discovery Senior Living, has closed a $64 million acquisition of a senior housing portfolio. This investment is part of a broader strategy to modernize and expand senior living communities to meet the rising demand for high-quality assisted living and memory care services. Discovery Senior Living will manage the properties, implementing its “experiential” living model. The deal highlights the continued interest of institutional real estate investors in the senior housing sector, driven by favorable demographic trends and the need for specialized care facilities. (Link)
Patient Advocate Foundation and PAN Foundation Announce Landmark MergerThe Patient Advocate Foundation (PAF) and the Patient Access Network (PAN) Foundation have announced their intention to merge, creating a powerhouse in the patient assistance sector. This merger will combine PAF’s case management and navigation services with PAN’s financial assistance programs for underinsured patients. By joining forces, the organizations aim to provide a more holistic support system for individuals facing life-threatening and chronic illnesses. The unified entity will focus on reducing financial barriers to care and improving health equity through expanded advocacy and direct patient support services. (Link)
Venture and Other News:
Minnesota Medical Technologies Secures $20 Million Series A Led by Versant Ventures Minnesota Medical Technologies (MMT) has closed a $20 million Series A funding round led by Versant Ventures, with participation from existing investors. MMT is a medical device firm focused on developing innovative solutions for urological and GI health. The capital will be used to accelerate the development and clinical validation of its flagship fecal incontinence treatment device. MMT aims to address a significant unmet need in the market with its minimally invasive technology, and the new funding will support toward FDA clearance and commercial launch in the U.S. market. (Link)
llumia Ventures Leads $20.5M Series B in Greater Good Health; DaVita Venture Group and Blue Cross of Idaho’s Granite Financial Join, with $12.5M Debt Facility from HSBC Innovation Banking Greater Good Health, a value-based primary care provider centered on nurse practitioners, raised $20.5 million in Series B funding led by Allumia Ventures, with participation from DaVita Venture Group, Granite Financial Holdings (Blue Cross of Idaho’s investment arm), and existing investors including Optum Ventures and Flare Capital Partners. The company also secured up to $12.5 million in venture debt from HSBC Innovation Banking. Serving over 200,000 patients, Greater Good Health will use the funds to expand its value-based care model, deepen payer partnerships, and extend its geographic footprint, addressing primary care shortages and rising healthcare costs. (Link)
NexCure Raises $19 Million Series A to Advance Immuno-Oncology Pipeline NexCure, a clinical-stage biopharmaceutical company, has successfully raised $19 million in a Series A funding round. While specific lead investors were not named in initial reports, the round included participation from several prominent life science venture firms. The funding will be directed toward advancing NexCure’s lead candidate through Phase 1 clinical trials and supporting the discovery of new drug targets for cancer immunotherapy. NexCure utilizes a proprietary functional screening platform to identify novel proteins that modulate the immune system, aiming to develop therapies for patients who do not respond to existing treatments. (Link)
Sage Secures $65 Million Series C Led by Goldman Sachs including ANEW Capital and Maveron to Scale AI Senior Care Platform Sage, a technology platform designed to modernize eldercare, has raised $65 million in a Series C funding round led by Goldman Sachs Asset Management. The round also saw participation from ANEW Capital and Maveron. Sage’s platform uses AI to help senior living staff monitor residents more effectively, prioritizing care based on real-time data to prevent emergencies. This new capital will be used to scale Sage’s operations, enhance its AI algorithms, and expand its reach into more senior living communities across the United States, addressing the critical staffing shortages in the industry. (Link)
Science Corporation Closes $230 Million Series C to Commercialize BCI Retinal Implant backed by Founders Fund, Lux Capital, and Paradigm Science Corporation, a leader in brain-computer interface (BCI) technology, has raised $230 million in a Series C round. The funding was backed by a diverse group of investors, including Founders Fund, Lux Capital, and Paradigm. The capital is earmarked for the commercialization of its PRIMA retinal implant, a sub-retinal device designed to restore vision in patients with geographic atrophy due to age-related macular degeneration. Following successful clinical results, Science Corp aims to use this massive infusion of capital to build out its manufacturing capabilities and prepare for a global product launch. (Link)
UnityAI Raises $8.5 Million Seed Round to Deploy AI Agents for Healthcare Workforce led by Max Ventures and General Catalyst UnityAI has secured $8.5 million in seed funding led by Max Ventures and General Catalyst. The startup is developing AI-driven “agents” designed to automate administrative tasks and optimize patient flow within hospital settings. The goal of the technology is to alleviate the burnout experienced by healthcare workers by handling scheduling, bed management, and documentation. This initial capital will allow UnityAI to expand its engineering team and launch pilot programs with several large health systems, proving the efficacy of AI in managing complex hospital operations and improving staff retention. (Link)
Grow Therapy Hits $3 Billion Valuation Following New Funding Round Led by TCV with participation from Transformation Capital and SignalFire Mental health platform Grow Therapy has reached a “unicorn” valuation of $3 billion after a new funding round led by TCV, with participation from Transformation Capital and SignalFire. Grow Therapy provides an integrated platform that helps independent therapists manage their practices while connecting patients with affordable, insurance-covered mental health care. The fresh capital will be used to further develop its AI-driven matching tools and expand its network of providers. The high valuation underscores the surging investor interest in mental health startups that solve the accessibility and affordability crisis. (Link)
KeyCare Raises $27.4 Million to Scale AI-Powered Epic-Based Virtual Care featuring 8VC, LRVHealth, and Health Catalyst Capital KeyCare, the nation’s first Epic-based virtual care company, has raised $27.4 million in a funding round featuring 8VC, LRVHealth, and Health Catalyst Capital. KeyCare allows health systems to expand their virtual care capacity by providing access to a network of independent “virtualist” providers who share the same EHR platform. This funding will support the expansion of KeyCare’s AI capabilities, which help triaging patients and streamlining the virtual visit process. By staying within the Epic ecosystem, KeyCare ensures seamless data sharing and continuity of care between virtual visits and in-person health system services. (Link)
Polares Medical Raises $50 Million Series C for U.S. Expansion of Mitral Valve Technology led by Decheng Capital and Endeavour Vision Polares Medical, a clinical-stage medical device company, has closed a $50 million Series C round led by Decheng Capital and Endeavour Vision. The company is developing the MRace Mitral Reshaping System, a hemi-replacement technology for treating mitral regurgitation. The funding will support the company’s expansion of clinical trials in the United States and the pursuit of regulatory approvals. Polares aims to provide a more physiological solution for heart valve repair, and this investment signifies strong investor confidence in the company’s unique approach to structural heart disease. (Link)
Teen-Built AI Calorie App “Cal AI” Generates $40 Million and Gains Interest from MyFitnessPal Cal AI, an AI-powered calorie-tracking app built by a 19-year-old entrepreneur during high school, has reportedly generated $40 million in revenue and attracted significant investment interest, including talks with MyFitnessPal and various Silicon Valley VCs. The app uses advanced computer vision to estimate caloric intake from photos of food with high accuracy. The success of the app highlights the power of “solopreneur” developers in the AI space. While a formal venture round hasn’t been closed, the founder is currently evaluating offers to scale into a broader metabolic health platform. (Link)
Ease Health Emerges from Stealth with $41 Million Led by Andreessen Horowitz (a16z) with support from Benchmark and F-Prime Capital. Ease Health has launched with $41 million in funding led by Andreessen Horowitz (a16z), with support from Benchmark and F-Prime Capital. The company is building what it describes as the “operating system for behavioral health,” a comprehensive software suite that integrates clinical notes, billing, and patient engagement for mental health clinics. By automating the “back-office” burden, Ease Health aims to allow therapists to focus more on patient care. The investment will be used to scale the platform nationally and integrate AI tools that help clinicians track patient progress over time. (Link)
Procode AI Raises $4 Million in Seed Funding to Automate Medical Coding round led by Eniac Ventures and Afore Capital Procode AI, a startup utilizing generative AI to automate medical coding and billing, has raised $4 million in a seed round led by Eniac Ventures and Afore Capital. The company’s platform analyzes clinical documentation in real-time to assign accurate medical codes, reducing errors and speeding up the reimbursement process for providers. This funding will be used to enhance the platform’s accuracy across different medical specialties and to expand the sales team. Procode AI enters a competitive market but aims to differentiate itself through its deep integration with existing EHR systems. (Link)
Trump’s Section 122 Tariffs Hit UK, EU Hardest as Supreme Court Strikes Down IEEPA Levies, Benefiting Brazil, China, India The U.S. Supreme Court ruled 6-3 that President Trump wrongly used IEEPA for tariffs, prompting a shift to 15% global duties under Section 122 of the 1974 Trade Act. Trade-weighted averages rise for UK (+2.1 points), EU (+0.8), Japan (+0.4), South Korea (+0.6), while plunging for Brazil (-13.6), China (-7.1), and India. Experts note heaviest IEEPA-hit nations gain most relief; early deal-makers suffer hikes. EU seeks clarity on prior 15% cap deal. China assesses; India delays trade talks. (Link)
Blue Owl Capital Shares Slide Again as Debt Fund Liquidity Changes and $1.4B Asset Sale Heighten Private Credit Concerns Blue Owl Capital’s stock extended its recent selloff as investors reacted to the firm’s strategy to return capital from one of its private debt funds following a $1.4 billion loan portfolio sale. The alternative asset manager adjusted redemption mechanics for Blue Owl Capital Corp II, opting to return capital through asset sales rather than traditional quarterly liquidity windows. The developments have fueled broader concerns around liquidity, valuation transparency, and structural risks within retail-oriented private credit vehicles. The market reaction underscores growing scrutiny of private credit managers as fundraising slows and pressures rise. (Link)
Cristiano Ronaldo Invests $7.5 Million in Herbalife’s (NYSE: HLF) Pro2col AI Wellness Tech, Secures 10% Stake in Key Subsidiary Herbalife Ltd. (NYSE: HLF) announced soccer superstar Cristiano Ronaldo’s $7.5 million investment in HBL Pro2col Software, LLC, gaining a 10% equity stake. The deal includes service and sponsorship commitments, highlighting Ronaldo’s faith in Pro2col’s AI-driven, personalized wellness platform. Since partnering with Herbalife in 2013, Ronaldo endorsed products like Herbalife24 CR7 Drive. Pro2col uses data for custom plans, tracks habits via Pro2Score, and aids distributors. Now in U.S., Canada, and Puerto Rico beta and expanding to EMEA, boosting their data-centric strategy. (Link)
True North PE Injects INR 150Cr ($16.5M) into High-Growth ACN Healthcare RCM; $20M More Eyed as India’s Outsourcing Boom Accelerates True North Private Equity’s Credit Opportunities Fund I invests Rs 150 crore in ACN Healthcare RCM, a top Revenue Cycle Management provider with India operations and US clients. ACN boasts 68% CAGR growth over three years, employing 3,000+ professionals across four centers. Funds will fuel service expansion, strategic moves, and new facilities. More PE funds eye up to $20M in the round. India’s RCM market surges at 15-17% CAGR, driven by outsourcing, AI, and global demand, with India holding 50% of worldwide talent amid healthcare complexities. (Link)
Danaher (NYSE: DHR) to Acquire Masimo (NASDAQ: MASI) in $9.9 Billion Cash Deal at $180/Share, Boosting Diagnostics with Pulse Oximetry Leader Amid Expected Synergies Danaher Corporation (NYSE: DHR) has agreed to acquire Masimo Corporation (NASDAQ: MASI) for $180 per share in cash, valuing the deal at $9.9 billion enterprise value. The acquisition bolsters DHR’s Diagnostics segment with MASI’s pulse oximetry and patient monitoring tech, expecting high-single-digit revenue growth, $530M+ 2027 EBITDA, $125M cost synergies, and $50M revenue synergies by year five. Deal closes H2 2026 pending approvals; accretive to EPS by $0.15-$0.20 year one, $0.70 by year five. (Link)
Johnson & Johnson (NYSE:JNJ) Explores $20 Billion Sale of DePuy Synthes Orthopedics Unit Amid Spinoff Plans Johnson & Johnson (JNJ.N) is preparing to sell its orthopedics unit, DePuy Synthes, in a deal potentially exceeding $20 billion, targeting private equity firms as top buyers, Reuters reports. The unit, which generated $9.3 billion in 2025 sales from hip, knee, and shoulder implants, was slated for a standalone spinoff within 18-24 months to focus on high-growth segments. J&J is assembling financials for upcoming buyer meetings; large PE firms may team up, with interest from medical device rivals possible. This follows resolutions of most ASR hip lawsuits. CFO eyes tax-free spinoff but open to sales. (Link)
PE-backed Elevate Patient Financial Solutions acquires Centauri Health Solutions’ health systems services unit, expanding Medicaid eligibility, enrolment and complex revenue cycle capabilities across U.S. hospital clients Private equity–backed Elevate Patient Financial Solutions has agreed to acquire Centauri Health Solutions’ Health Systems Services (HSS) unit, a Phoenix-based provider of specialized eligibility and enrollment services for Medicaid and disability programs, out-of-state Medicaid billing, and complex revenue cycle solutions for hospitals and health systems. The deal strengthens Elevate PFS’s position in patient financial engagement and government program eligibility, broadens its national footprint, and is expected to drive cross-selling opportunities across existing provider relationships while supporting uncompensated-care and Medicaid-reliant populations. (Link)
TriSalus Life Sciences (Nasdaq: TLSI) Prices $40M Common Stock Offering at $4.10/Share with 15% Over-Allotment Option, Closing February 23, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) priced its underwritten public offering of 9,756,100 common shares at $4.10 each, expecting $40 million in gross proceeds before expenses. The oncology-focused medtech firm granted underwriter Lake Street Capital Markets a 30-day option for 1,463,415 additional shares (15% of the offering). Closing is set for February 23, 2026, subject to conditions, via an effective S-3 shelf registration. Funds will support general corporate purposes, amid devices like TriNav for tumor drug delivery and nelitolimod immunotherapy research. (Link)
CenterWell, the healthcare services division of Humana Inc. (NYS: HUM) Expands Florida Footprint with Acquisition of MaxHealth from Arsenal Capital Partners CenterWell, the healthcare services division of Humana Inc., has completed its acquisition of MaxHealth from private equity firm Arsenal Capital Partners and the company’s founder-shareholders. The deal strengthens CenterWell’s presence in Florida, adding a network of 54 owned primary care clinics, four specialty centers, and 24 affiliate clinics across West and South Florida. MaxHealth serves over 120,000 patients, including more than 80,000 in value-based care programs. The acquisition aligns with CenterWell’s strategy to expand its integrated, patient-centered care delivery network and enhance access to high-quality, coordinated healthcare services for seniors and other patients across the region. (Link)
CSD Acquires New Mexico’s Leading Autism Provider BCI in Strategic Merger to Boost Southwest Access, Innovation, and Evidence-Based Behavioral Care Nationwide via its financial sponsors NMS Capital, CD Private Equity, and Goldman Sachs Asset Management Center for Social Dynamics (CSD), a top national autism therapy provider, has acquired Behavior Change Institute (BCI), New Mexico’s premier autism care organization known for clinical expertise and equitable access. Announced February 19, 2026, the deal unites research-driven models, shortening wait times and blending in-person, virtual, and tech-enhanced therapies. CSD CEO Kelly Bozarth hailed it as a “values-driven union” for faster breakthrough care. BCI leaders emphasized scaling their mission nationally while preserving clinical culture. Families retain teams with added CSD tools; the merger advances research, clinician training, and outcomes in underserved areas. (Link)
VB Spine LLC Acquires Exclusive Rights to Augmedics’ FDA-Cleared xvision Spine System®, Bolstering AR Navigation Leadership in Spine Surgery with Nearly 13,000 Cases of Proven Use VB Spine LLC, the largest privately held spine company, announced a definitive agreement to acquire exclusive rights to Augmedics’ groundbreaking xvision Spine System®, the first FDA-cleared AR navigation platform for spine surgery. This move enhances VB Spine’s visualization portfolio, following its recent SpineHawk™ acquisition, and positions it as a global leader in AR-enabled solutions. xvision offers direct-patient visualization, precision, workflow efficiency, and radiation reduction, with nearly 13,000 procedures completed. The deal, expected to close soon pending approvals, supports VB Spine’s strategy to redefine spine care. (Link)
St. David’s HealthCare Acquires Cardiothoracic and Vascular Surgeons, Strengthening Central Texas Cardiovascular Expertise in Strategic Integration Austin-based St. David’s HealthCare, part of HCA Healthcare and local nonprofits, has acquired Cardiothoracic and Vascular Surgeons (CTVS) on Feb. 15. The system, with nine hospitals, 190 care sites, and over 12,600 employees, will keep CTVS’s name, operations, physicians, providers, and 45 staff intact while aligning them under St. David’s. “This integration builds on decades of collaboration to elevate care and innovation,” said CEO David Huffstutler. The move advances cardiovascular standards in Central Texas. (Link)
Epiphany Dermatology Expands Missouri Footprint with Strategic Partnership Joining Regional Dermatology’s St. Louis Clinics in Chesterfield and Festus Epiphany Dermatology has partnered with Regional Dermatology, LLC, founded in 2010 by board-certified dermatologist Sarah Jensen, M.D., to boost its presence in Missouri’s St. Louis market. The deal integrates Jensen’s team—including two advanced practice providers—at two locations: Chesterfield (West) and Festus. This enhances access to high-quality dermatology services like general care, skin cancer treatment, and Mohs surgery. Jensen praised Epiphany’s patient-focused values, while CEO Gheorghe Pusta highlighted the cultural fit and shared expertise. Epiphany now supports operations, marketing, and recruiting, operating 121 locations across 18 states from Austin, Texas. (Link)
Gilead to Acquire Arcellx for Up to $7.8 Billion, Expanding Oncology and Cell Therapy Pipeline Gilead Sciences has agreed to acquire Arcellx in a transaction valued at up to $7.8 billion, strengthening its position in next-generation cell therapies for cancer. Arcellx’s lead programs focus on innovative immunotherapy approaches designed to improve durability and safety in hematologic malignancies. The acquisition builds on Gilead’s broader oncology strategy and deepens its commitment to high-growth, high-innovation therapeutic areas. The deal underscores continued large-cap biopharma appetite for differentiated oncology assets amid competitive cell therapy development. (Link)
Viventium Acquires Apploi to Launch Unified HCM Platform Revolutionizing Post-Acute Care Workforce Management Amid Labor Crisis via its financial sponsor LLR Partners Viventium has acquired Apploi, creating a category-leading human capital management (HCM) platform tailored for post-acute and long-term care providers. The unified system integrates recruiting, credentialing, onboarding, payroll, scheduling, and compliance across all 50 states, addressing labor shortages and fragmented software silos. Viventium CEO Navin Gupta highlighted ending “fractured systems,” while Apploi CEO Adam Lewis emphasized full employee lifecycle support. Serving thousands of providers and hundreds of thousands of employees, the deal closed January 30, 2026. Financial terms undisclosed. (Link)
Invo Fertility (Nasdaq: IVF), Acquires Indianapolis’ Family Beginnings for $760K, Bolstering Midwest Presence and Projecting $9M Clinic Revenue in 2025 Amid Growth Pivot Invo Fertility Inc. (Nasdaq: IVF), based in Sarasota, has acquired the nonclinical assets of Midwest fertility clinic Family Beginnings in Indianapolis for $760,000 in cash and preferred stock. The deal preserves Dr. James Donahue’s leadership and the existing team, with Invo providing operational support and tech investments. Family Beginnings reported $1M revenue and $200K net income for the nine months ended Sept. 30, 2025—18% of Invo’s clinic revenue. Now with four clinics, Invo eyes $9M combined 2025 revenue, up from 2024’s $6.5M total (with $9.1M net loss). CEO Steve Shum calls it an “inflection point,” targeting acquisitions, organic growth, and 2026 expansion via marketing and tech. (Link)
Northwell Health Bolsters South Shore Presence with $9.5M Off-Market Acquisition of Merrick Orthopedic Office Building from Berkeley Capital Northwell Health has expanded its real estate holdings by acquiring a 17,714-square-foot medical office building at 1728-1732 Sunrise Highway in Merrick for $9.5 million in an off-market deal. The property, on 0.46 acres, houses Northwell affiliate Orlin & Cohen Orthopedic Group, with about three years remaining on its lease. Northwell, self-represented, bought from Berkeley Capital LLC, represented by North Village Realty’s Tom Bigansky. The move secures long-term healthcare delivery in South Shore communities, reflecting generational planning and market confidence, Bigansky noted. (Link)
Sensei Biotherapeutics (Nasdaq: SNSE) Acquires Faeth Therapeutics in $200M-Backed Deal to Advance PIKTOR Cancer Therapy Sensei Biotherapeutics (Nasdaq: SNSE) has acquired Faeth Therapeutics, gaining its lead asset PIKTOR—an investigational all-oral combo of serabelisib and sapanisertib targeting the PI3K/AKT/mTOR pathway for endometrial and breast cancers. Concurrently, Sensei secured $200 million in Series B preferred stock financing from top investors like RA Capital, Vivo Capital, and Cormorant. Proceeds will fund Phase 2 topline data in endometrial cancer and a Phase 1b breast cancer trial by end-2026, plus ongoing solnerstotug studies. Post-deal, Faeth holders own 40.8%, investors 54.3%, and prior Sensei shareholders 4.9% on a fully diluted basis. (Link)
Kinderhook Industries to Take Home Health and Hospice Provider Enhabit (NYSE: EHAB) Private in $1.1B Deal Private equity firm Kinderhook Industries has agreed to acquire Enhabit Inc., a Dallas-based home health and hospice services provider, in a transaction valued at approximately $1.1 billion. Under the terms of the deal, Enhabit shareholders will receive $13.80 per share in cash, representing a premium to the company’s recent trading levels. The transaction is expected to close in Q2 2026, at which point Enhabit’s shares will be delisted from the NYSE. The acquisition reflects continued PE interest in the home health and hospice sector amid demographic tailwinds and demand for at-home care services. (Link)
Venture and Other News:
Rainfall Health Secures $15M Series A to Supercharge AI Compliance Platform Amid CMS’s TEAM Mandate Launch, Unlocking $100M+ Revenue for Hospitals Rainfall Health, an AI-driven compliance platform for hospitals, closed a $15 million Series A round led by Two Bear Capital. The funding will expand AI and customer support teams to aid providers under CMS’s new Transforming Episode Accountability Model (TEAM), launched January 1, 2026. TEAM targets high-cost surgeries like joint replacements and spinal fusions, offering 20% revenue boosts—over $100 million per health system—for meeting quality metrics. CEO Eddie Qureshi emphasized high-quality post-acute care. Backed by experts like former VA Secretary David Shulkin, Rainfall sets a national standard for value-based reimbursement and patient outcomes. (Link)
ProSomnus Secures $38 Million Strategic Investment from Catalio Capital to Advance Next‑Generation Smart Sleep Medicine Platform ProSomnus Sleep Technologies, a leader in non‑CPAP Obstructive Sleep Apnea (OSA) therapy, announced a $38 million strategic investment from healthcare investor Catalio Capital Management to accelerate global expansion and technology development. The funding will support next‑generation remote patient monitoring, proprietary sleep diagnostic devices, and comparative clinical studies. CEO Len Liptak emphasized that the partnership validates ProSomnus’s mission to deliver data‑driven, patient‑preferred OSA therapies. CFO Jason Orchard noted the investment will optimize infrastructure and enhance patient outcomes. Catalio’s Dr. Nicholas von Guionneau joins as Board Observer, highlighting ProSomnus’s leadership in connected, precision sleep solutions. (Link)
Dallas-Based SpendRule Exits Stealth with $2M Seed Round from Abundant Venture Partners, MemorialCare Innovation Fund, and Zeal Capital Partners to Automate AI-Powered Contract Compliance and Invoice Validation for Hospitals like OSF HealthCare, Kettering Health, MemorialCare, and MUSC Health SpendRule, founded by Chris Heckler and Joseph Akintolayo, automates contract compliance and invoice validation for health systems. Its AI software checks purchased services invoices against contract terms pre-payment, integrating seamlessly with ERP systems, contract management, and accounts payable workflows. The funding will expand the team and advance AI infrastructure. Backed by Abundant Venture Partners—a Chicago VC focused on healthcare innovation with a network of 22+ provider organizations—SpendRule serves major clients including OSF HealthCare, Kettering Health, MemorialCare, and MUSC Health. (Link)
Covetrus and MWI Animal Health Strike $3.5 Billion Merger Deal, Forming Tech-Enhanced Platform with Cencora Retaining Major Stake Covetrus and MWI Animal Health announced a blockbuster $3.5 billion merger on February 18, creating a unified “comprehensive animal health platform.” MWI’s owners, Cencora, will receive $1.25 billion in cash and equity stakes, retaining a 34.3% share in the new entity. Leaders hailed the deal for blending MWI’s supply chain prowess and customer ties in companion and production animal sectors with Covetrus’ tech-driven veterinary solutions. The combo promises enhanced logistics, cost savings, broader customer reach—from vets and producers to pet owners—and accelerated innovation to make animal care more affordable and accessible. (Link)
Grail’s Galleri Multi-Cancer Early Detection Blood Test Misses Primary Endpoints in Large Screening Trial Grail’s Galleri multi-cancer early detection blood test recently failed to meet its primary endpoints in a large clinical screening study, raising doubts about its effectiveness as a broad population screening tool. Following the release of these results, the company’s stock experienced a significant decline as investors reassessed commercial prospects. The data suggested lower than expected sensitivity for detecting certain cancers, which could complicate regulatory and reimbursement pathways. The outcome underscores ongoing challenges for next-generation liquid biopsy tests in proving clinical utility at scale. (Link)
Ro: Serena Williams promotes GLP-1 telehealth. (Link)
Novartis: Encourages prostate cancer blood test screening. (Link)
Boehringer Ingelheim: Raises awareness for kidney disease screening. (Link)
TrumpRx launches with AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer to offer discounted drugs for U.S. cash‑paying patients under Most favoured Nation policy The TrumpRx direct‑to‑consumer platform introduces over 40 discounted prescription drugs to help uninsured or cash‑paying U.S. patients access more affordable treatments. The initiative, backed by the first five pharmaceutical companies signing pricing deals under the Most Favoured Nation policy, includes major blockbusters such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, both offered at significantly reduced prices. Additional products include insulin, fertility therapies, and inhalers from Pfizer and others. Sixteen global drugmakers are expected to join the platform, which aims to align U.S. medication prices with international standards while reshaping the domestic pricing landscape and consumer access dynamics. (Link)
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal Takeda Pharmaceutical enters multi-year AI drug discovery collaboration with Iambic Therapeutics worth more than $1.7 billion to accelerate small-molecule development in oncology, inflammation, and gastrointestinal diseases. The partnership underscores Takeda’s push to fully integrate AI into its R&D engine, following prior deals like its Nabla Bio collaboration, as big pharma bets on AI to speed discovery, reduce costs, and target complex diseases more precisely. Iambic, a San Diego-based biotech with a growing pipeline of AI-discovered candidates, gains validation and funding to expand its platform amid surging interest in AI-driven drug design. (Link)
Once Upon a Farm (NYSE: OFRM) raises $198M in NYSE IPO backed by Goldman Sachs and J.P. Morgan to expand organic children’s food business co-founded by Jennifer Garner The company’s public debut marks a major milestone for the organic children’s food brand, offering 11 million shares at $18 each. Founded by Cassandra Curtis and Ari Raz in 2015 and later joined by Jennifer Garner and John Foraker, Once Upon a Farm produces cold-pressed pouches, frozen meals, and oat bars made from responsibly sourced fruits and vegetables. The IPO strengthens its ability to meet rising consumer demand for clean, nutritious food products while amplifying its retail presence. Despite global supply challenges, the company aims to grow amid increasing momentum in the health-conscious food and beverage market. (Link)
TenetHealthcare (NYSE: THC) receives $1.9B from CommonSpirit to regain full ownership of Conifer Health Solutions Under the agreement, CommonSpirit will pay Tenet Healthcare $1.9 billion in instalments over three years to sell its 23.8% equity stake in Conifer Health Solutions, Tenet’s revenue cycle management subsidiary. The transaction, retroactive to January 1, 2026, also includes a $540 million payment from Conifer to eliminate CommonSpirit’s capital account and finalize the stake redemption. Conifer will continue providing services to CommonSpirit through the end of 2026 while onboarding new clients. Tenet expects the move to strengthen its financial outlook, citing operational efficiency, revenue growth, and strategic alignment as key drivers for sustaining profitability and future expansion. (Link)
PrimeGen US to merge with DT Cloud Star Acquisition Corporation (NASD: DTSQ) in a $1.5B business combination to accelerate stem cell and exosome therapy development The merger will position PrimeGen US for public market access and expanded funding to advance its regenerative medicine portfolio. The company’s lead program centers on its proprietary Triple Activated Mesenchymal Stem Cell (MSC) platform, being developed as a treatment for acute alcoholic hepatitis and other liver-related conditions. The deal, expected to close in the second half of 2026 pending shareholder and regulatory approvals, will support clinical progression, regulatory submissions, and potential commercialization. PrimeGen’s leadership emphasized that the transaction marks a major step toward scaling its two-decade foundation in stem cell innovation into transformative therapies for critical diseases. (Link)
Eikon Therapeutics (NASD: EIKN) raises $381M in upsized Nasdaq IPO, the largest biotech listing since 2024, led by former Merck executive Roger Perlmutter Proceeds from the public offering will fund the clinical advancement of Eikon’s oncology pipeline, notably EIK1001, a toll-like receptor 7/8 agonist currently studied with Keytruda in melanoma and lung cancer. Additional programs include PARP1 inhibitors EIK1003 and EIK1004—targeting ovarian, breast, prostate, and pancreatic cancers—and EIK1005, a WRN helicase inhibitor in early-stage development for solid tumours. The company, founded in 2021, continues to build momentum on its immunotherapy and precision oncology strategy, backed by prior multimillion-dollar financing rounds that have supported rapid progression from preclinical research to multiple active phase 1/2 and 2/3 trials across critical cancer indications. (Link)
SpyGlass Pharma (NASD: SGP) launches $150M Nasdaq IPO for advancing long-acting eye drug delivery innovation Funds from the IPO will advance SpyGlass Pharma’s lead candidate, the Bimatoprost Drug Pad-IOL System, a long-acting intraocular lens designed to deliver sustained treatment for glaucoma and ocular hypertension. The device, implanted during cataract surgery, provides years of drug release, potentially eliminating the need for daily eye drops. Proceeds will support two phase 3 clinical trials already underway and a potential commercial rollout upon successful results. Early studies demonstrated significant intraocular pressure reduction, affirming the platform’s promise. SpyGlass joins a wave of biotech companies reinvigorating the IPO market as investors renew interest in ophthalmic and drug-delivery innovations. (Link)
Agomab Therapeutics (NASD: AGMB) raises $200M in Nasdaq IPO to support development of ALK5 inhibitors for fibrostenosing Crohn’s disease and pulmonary fibrosis Proceeds from the IPO will fund Agomab Therapeutics’ next-stage clinical programs, including a global phase 2b trial for ontunisertib, its leading oral ALK5 inhibitor targeting fibro stenosing Crohn’s disease. The company also plans to advance AGMB‑447, another ALK5 inhibitor in phase 1 studies for idiopathic pulmonary fibrosis, toward midstage development. Both candidates were obtained through Agomab’s 2021 acquisition of Origo Biopharma. The IPO proceeds will also bolster operational growth and global research capabilities as Agomab pursues fibrosis-modifying therapies aimed at halting disease progression in patients with chronic intestinal and respiratory conditions. (Link)
Veradermics (NYSE: MANE) raises $256M in NYSE IPO with investment interest from Eli Lilly and Wellington Management to advance oral minoxidil hair regrowth therapy The Connecticut-based biotech’s IPO marks a strong debut, with shares more than doubling in their first trading session. Veradermics focuses on developing VDPHL01, an extended-release oral version of minoxidil, intended to overcome limitations of topical Rogaine. The funds will support phase 3 trials evaluating its efficacy in treating pattern hair loss. Eli Lilly expressed interest in acquiring up to 4.9% of issued shares, while Wellington Management indicated plans to invest up to $30 million. The company seeks to capture a major share of the expanding global hair loss market and lead innovation in convenient, effective hair restoration therapies. (Link)
Kaiser Permanente and Renown Health complete joint venture to jointly own Hometown Health and expand integrated care access in northern Nevada The finalized partnership marks Kaiser Permanente’s entry into northern Nevada through the joint ownership of Hometown Health and collaboration with Renown Health’s established provider network. The venture aims to expand access to affordable, value-based care while integrating insurance coverage and clinical delivery across the region. Kaiser Permanente will open two new medical centers in 2026, adding to its existing Reno location, and plans to introduce its digital health platform and in-house pharmacy network by 2027. The collaboration combines Kaiser Permanente’s national capabilities with Renown’s strong local presence to enhance clinical outcomes and improve patient experience across northern Nevada. (Link)
NuvemRx acquires 340B referral technology company par8o from R1 RCM, via its financial sponsors Parthenon Capital Partners and Rainmaker Strategic Capital to enhance specialty care coordination and expand pharmacy network capabilities The acquisition integrates par8o’s AI-powered referral capture technology with NuvemRx’s pharmacy management and third-party administration services, enabling covered entities to more efficiently manage 340B referrals and specialty prescriptions. The combined platform now supports over 800 covered entities and impacts more than 70 million patients nationwide. By automating up to 85% of the referral and eligibility process, the integration reduces administrative burdens, enhances compliance, and increases savings opportunities for safety-net providers. The move strengthens NuvemRx’s mission to simplify pharmacy operations, expand access to affordable care, and improve coordination across community health and specialty care networks. (Link)
MedRisk to acquire Horizon Casualty Services PPO Network business from Horizon Mutual Holdings, via its financial sponsors CVC Capital Partners and The Carlyle Group to expand managed care capabilities in workers’ compensation and auto casualty markets The acquisition enhances MedRisk’s reach and service offerings within the casualty claims industry by integrating Horizon Casualty Services’ PPO Network business. The move aligns with MedRisk’s strategy to deliver improved patient outcomes, streamlined claims management, and optimized payment solutions. The integration supports faster recovery times, smarter spending, and enhanced client value while reinforcing the company’s commitment to innovation and superior service across workers’ compensation and auto casualty markets. (Link)
Coloplast discloses definitive agreement for Uramedica acquisition in Q1 2025/26 earnings Report Coloplast US signs definitive merger agreement to acquire all outstanding shares of Uromedica, a privately held US medtech company specializing in minimally invasive treatments for stress urinary incontinence, making Uromedica a wholly owned subsidiary. The acquisition is expected to close in February 2026, subject to customary closing conditions and requisite Uromedica shareholder approval. The move aligns with Coloplast’s strategy to bolster growth in urology through targeted additions, amid strong organic performance in the division. (Link)
Konovo acquires Rare Patient Voice, via its financial sponsors Bain Capital Credit, Frazier Healthcare Partners, GV Investment Managers and Leavitt Equity Partners to expand access to 200,000+ patients and caregivers The acquisition strengthens Konovo’s healthcare intelligence platform by combining its data-driven capabilities and healthcare provider network with Rare Patient Voice’s extensive, community-driven database of patients and caregivers. This integration enhances the ability of researchers to access hard-to-reach populations and capture real-world patient insights across therapeutic areas. Konovo plans to scale these efforts globally while integrating patient and clinician perspectives into unified, technology-enabled research solutions. The partnership drives faster, more informed decision-making for healthcare organizations advancing innovation in complex diseases. (Link)
RadNet (NASD: RDNT) acquires Northwest Radiology in Indiana, adding six imaging centers to expand Midwest footprint and enhance AI-powered diagnostic services The acquisition marks RadNet’s entry into Indiana, extending its national imaging network into the Midwest through six outpatient centers in the Indianapolis region. Northwest Radiology’s 18 radiologists will continue providing contracted professional services, ensuring continuity and maintaining strong local physician relationships. The integration will leverage RadNet’s advanced imaging technologies and AI-driven workflows to improve early disease detection and overall population health management. With the addition expected to generate approximately $18 million in annual revenue, RadNet aims to expand its proactive diagnostic approach while strengthening patient access to high-quality, cost-effective imaging care across Indiana. (Link)
Nautic Partners completes growth investment in KabaFusion as Novo Holdings exits, supporting expansion of home infusion care services The partnership marks a new phase for KabaFusion, a national leader in home and alternate site infusion therapy. With operations covering 45 states through 33 pharmacies and 21 infusion suites, the company will leverage Nautic Partners’ investment to accelerate its growth and innovation initiatives. KabaFusion’s management team, which remains significant investors, will continue leading the organization to enhance patient access and clinical excellence. The investment underscores Nautic’s strategy of backing mission-driven healthcare providers delivering high-quality, patient-centered care, marking the exit of Novo Holdings following its successful tenure supporting KabaFusion’s nationwide expansion. (Link)
Black Pearl Equities Announces Intention to Commence Tender Offer to Acquire Selectis Health, Inc. Black Pearl Equities, LLC announces intention to commence an all-cash tender offer to acquire all issued and outstanding shares of common stock of Selectis Health, Inc. (OTC: GBCS) at $4.00 per share. The proposed transaction is subject to negotiation and execution of definitive transaction documentation as well as customary closing conditions. Selectis Health operates skilled nursing and transitional care facilities, and this unsolicited proposal follows the company’s recent asset sales and operational streamlining efforts. (Link)
Vanderbilt Health acquires Tennova’s Clarksville Hospital, Tennova ER-Sango, and physician clinics from Community Health Systems to expand regional care network The acquisition expands Vanderbilt Health’s footprint across Middle Tennessee, adding the 270-bed Clarksville hospital, freestanding Sango ER, and multiple physician practices to its growing regional system. Vanderbilt Clarksville Hospital (VCH) will serve as a hub for expanded emergency, surgical, and specialty services, with new paediatric and adult programs planned in collaboration with Monroe Carell Jr. Children’s Hospital. The integration brings nearly 1,100 staff and over 30 physicians into Vanderbilt’s network, reinforcing its commitment to delivering high-quality, community-based care. The move marks Vanderbilt’s fourth regional hospital acquisition, extending its reach beyond Nashville and strengthening access to advanced health services statewide. (Link)
Venture and Other News
Midi Health closes $100M Series D in Goodwater Capital–led round with Foresite Capital, Serena Ventures, Advance Venture Partners, GV, Emerson Collective, SemperVirens and McKesson Ventures to scale national women’s health platform The virtual women’s health clinic now serves over 230,000 patients across 50 states through a network of 500 providers, treating 25,000 patients weekly. Founded in 2021 to address perimenopause and menopause care, the company is expanding into metabolic health, weight management, and musculoskeletal health. The platform uses AI-powered tools for chart analysis, scheduling, and care protocols while offering insurance-backed services reaching 45 million women. The company reports improved screening adherence rates and up to 13% lower total cost of care, with plans to expand Medicare and Medicaid coverage. (Link)
Chamber raises $60M Series A led by Frist Cressey Ventures with General Catalyst, AlleyCorp, American Family Ventures, Company Ventures, Optum Ventures, Healthworx Ventures and Black Opal Ventures to scale cardiology value-based care The funding will accelerate Chamber’s mission to modernize cardiovascular care through value-based models that improve outcomes while lowering costs. The company’s platform integrates AI-driven insights to help cardiologists identify high-risk patients, close care gaps, and streamline workflows within existing systems. Partnering with both payers and practices, Chamber supports data-informed, proactive management of chronic heart disease. With more than 500 cardiologists across seven states already on its network, the company plans to expand its national footprint and strengthen partnerships with health plans. The investment underscores growing momentum behind value-based innovations addressing cardiovascular care delivery and patient experience. (Link)
Alaffia Health raises $55M Series B led by Transformation Capital with FirstMark Capital, Tau Ventures, and Twine Ventures to expand AI-driven health plan operations The latest funding round accelerates Alaffia Health’s mission to reduce healthcare’s $570 billion in administrative waste through advanced, clinically informed AI for health plan claims management. The company’s platform combines physician oversight with agentic AI to enhance accuracy, speed reviews, and achieve measurable cost savings for national and regional payers. Delivering over 20% savings on high-cost claims and fivefold ROI, Alaffia plans to use the new capital for R&D, product innovation, and scaling adoption across the healthcare ecosystem. The investment supports ongoing efforts to create transparent, compliant, and efficient claims infrastructure that strengthens affordability and systemwide operational performance. (Link)
Third Arc Bio raises $52M Series A extension led by Andreessen Horowitz with Omega Funds, Goldman Sachs Alternatives, BVF Partners, T. Rowe Price, Galapagos NV, AbbVie Ventures and Alderline Group to advance oncology and immunology pipeline The funding strengthens Third Arc Bio’s efforts to expand its multifunctional antibody programs in oncology and immunology. The capital will accelerate clinical development of the company’s lead asset, ARC101—a bispecific T cell engager targeting CLDN6 in advanced solid tumours—while advancing next-generation inflammation and immune modulation candidates toward human trials. Leveraging its ARCTag (Tethered Agonist) platform, Third Arc Bio aims to localize immune activity precisely at disease sites, enhancing efficacy and reducing systemic toxicity. Supported by a seasoned scientific team, the company continues to validate its platform approach to develop targeted biologics addressing major unmet medical needs. (Link)
Market Rumours
Seed Health reportedly retains Centerview Partners to explore potential sale amid strong financial performance Seed Health has reportedly hired Centerview Partners to advise on a potential sale as it attracts strong interest from strategic and private equity buyers. Generating about $200 million in revenue and over $50 million in EBITDA, the company aims to leverage rising global demand for premium probiotics and wellness products.
HHAeXchange reportedly explores sale with Centerview Partners advising; backed by Cressey & Company and Hg Capital The company, generating about $100 million in recurring revenue, develops software that streamlines compliance and operations for Medicaid homecare providers. Having expanded through acquisitions of Sandata Technologies, Generations Homecare Systems, and Cashe Software, it reflects growing investor interest in post‑acute healthcare tech consolidation during ongoing strategic review discussions.
